Helix BioMedix, Inc.
HXBM
$7.18
-$0.01-0.14%
OTC PK
| 09/30/2012 | 06/30/2012 | 03/31/2012 | 12/31/2011 | 09/30/2011 | |
|---|---|---|---|---|---|
| Revenue | 14.56% | 32.56% | 94.29% | 122.06% | 221.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.56% | 32.56% | 94.29% | 122.06% | 221.16% |
| Cost of Revenue | -6.19% | 8.40% | 130.45% | 181.61% | 278.46% |
| Gross Profit | 27.23% | 47.99% | 77.84% | 95.87% | 194.07% |
| SG&A Expenses | 20.51% | 12.74% | 10.96% | 8.00% | 5.61% |
| Depreciation & Amortization | -13.52% | -9.54% | -5.12% | -4.13% | -8.44% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.13% | 1.61% | 7.93% | 11.43% | 13.76% |
| Operating Income | -1.53% | 15.68% | 25.73% | 20.44% | 23.54% |
| Income Before Tax | 61.22% | 66.50% | 68.50% | 67.73% | -71.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 61.22% | 66.50% | 68.50% | 67.73% | -71.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 61.22% | 66.50% | 68.50% | 67.73% | -71.36% |
| EBIT | -1.53% | 15.68% | 25.73% | 20.44% | 23.54% |
| EBITDA | -2.26% | 15.95% | 26.55% | 21.10% | 24.14% |
| EPS Basic | 72.47% | 78.04% | 80.57% | 81.20% | -24.55% |
| Normalized Basic EPS | 22.49% | 50.67% | 62.81% | 66.39% | 55.86% |
| EPS Diluted | 72.47% | 78.04% | 80.57% | 81.20% | -24.55% |
| Normalized Diluted EPS | 22.49% | 50.67% | 62.81% | 66.39% | 55.86% |
| Average Basic Shares Outstanding | 10.06% | 26.97% | 50.02% | 83.30% | 76.08% |
| Average Diluted Shares Outstanding | 10.06% | 26.97% | 50.02% | 83.30% | 76.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |